Gary R. Lichtenstein, MD

faculty photo
Professor of Medicine (Gastroenterology) at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
3400 Civic Center Boulevard
753 Perelman Center for Advanced Medicine
South Pavilion
Philadelphia, PA 19104
Office: 215-349-8222
Fax: 215-349-5915
BA (Chemistry)
University of Pennsylvania, 1980.
Mount Sinai School of Medicine, 1984.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

My research focuses on inflammatory bowel disease specifically Crohn's disease and Ulcerative Colitis. My particular focuses include
1.) medical therapy of inflammatory bowel disease,
2.) safety of current medical therapy for IBD, and
3.) natural history of disease

Description of Clinical Expertise

Inflammatory Bowel Disease
Crohn's Disease
Ulcerative Colitis

Selected Publications

Armuzzi A, Cross RK, Lichtenstein GR, Hou J, Deepak P, Regueiro M, Wolfm DC, Akukwe L, Ahmad HA, Jain A, Kozinn M, Wu H, Petersen AK, Charles L, Long M.: Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses. Clincial Gastroenterology and Hepatology 2023.

Lichtenstein GR. : Virtual Reality and Disorders of Gut-Brain Interaction. Gastroenterol Hepatol (N Y). (eds.). 2023.

Weber A. and Lichtenstein GR.: Evidence-Based Approach to Chronic Antibody-Refractory Pouchitis (CARP): A Review. Disease of the Colon and Rectum 2023.

Gary R. Lichtenstein, Scott D. Lee, Brian G. Feagan, Edward V. Loftus, Samson Ng, Kaitlin Dehlin, and others. : PREGNANCY OUTCOMES IN CROHN'S DISEASE PATIENTS EXPOSED TO CERTOLIZUMAB PEGOL: SAFETY DATA FROM THE SECURE REGISTRY Gastroenterology 2023.

Remo Panaccione, Gary Roth Lichtenstein , Hiroshi Nakase, Alessandro Armuzzi, Torsten Kucharzik, Gweneth Levy, Hannah Palac, Michelle Kujawski, Justin klaff, Jae Hee Cheon : SAFETY OF UPADACITINIB IN ULCERATIVE COLITIS: LONG-TERM DATA FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE) Gastroenterology 2023.

Khan, R.M.Q, Schwartz, D.A, Sands, B.E, Hanauer, S, Uddin, S, Mukherjee, R, Lichtenstein, G. : Clinical trial design in Crohn’s disease: interpreting future endpoints based on post hoc analyses of the vedolizumab phase 3 trials GEMINI 2 and VISIBLE 2. Journal of Crohn’s and Colitis 2023.

Bhattacharya A, Travis D, Osterman MT, Lewis JD, Bhagya Rao B, Lee H, Lichtenstein GR.: Supratherapeutic Infliximab Levels Do Not Predict Risk of Short-term Complications in Adults With Crohn's Disease. J Clin Gastroenterol. 2023.

Lichtenstein GR. : Liver Transplant in Patients With Obesity. Gastroenterol Hepatol (N Y). 2023 Notes:

Mukherjee, Qasim Rana Khan, Julia J. Liu, Ashwin Ananthakrishnan, Gary Roth Lichtenstein, Sharif M. Uddin, Lisa Young, Mena Boules, Paula Adamson, Vonda Reeves Richa Sagar : EFFICACY AND SAFETY OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS STRATIFIED BY ETHNICITY AND RACE: A POOLED ANALYSIS OF DATA FROM GEMINI 1, VARSITY, AND VISIBLE 1. Gastroenterology 2023.

Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinano M, Huang K-H,SHipitofsky N, Zhang H,Wilson, R, Han C, Feagan BG, Sandborn WJ, Panes J, Hisamatsu T, Lichtenstein GR, Sands BE and Dignass A.: Guselkumab In Patients with Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study. Gastroenterology 2023.

back to top
Last updated: 12/15/2023
The Trustees of the University of Pennsylvania